Cell Response and Regulation (CRR)

细胞反应与调节 (CRR)

基本信息

批准号：
10152544
负责人：
Trudy Gale Oliver
金额：
$ 6.62万
依托单位：
UNIVERSITY OF UTAH
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-05-09 至 2025-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10152544
关键词：
Address American Cancer Society Area Award Back Basic Science Cancer Biology Cancer Center Cancer Center Support Grant Cancer Control Cancer Model Cause of Death Cell Cycle Stage Cell Death Cell Fate Control Cell Proliferation Cells Cellular biology Clinic Clinical Collaborations Department of Defense Development Diagnostic Disease Disseminated Malignant Neoplasm Distant Doctor of Philosophy Drosophila genus Drug Targeting Education Effectiveness Embryo Environment Fostering Foundations Funding Genetically Engineered Mouse Goals Grant Human Infrastructure Institutes Investigation Investigational Therapies Journals Malignant Neoplasms Mediating Metastatic to Mission Modeling Neoplasm Metastasis Organoids Paper Pathway interactions Patients Peer Review Peer Review Grants Population Population Sciences Pre-Clinical Model Prevention Principal Investigator Publications Publishing Regulation Research Research Personnel Resistance Resource Sharing Safety Schools Science Scientist Signal Pathway Signal Transduction Signaling Molecule Site Solid Neoplasm Strategic Planning Sushi Domain System Testing Training Translating United States National Institutes of Health Universities Utah Work Xenopus Zebrafish biomarker development cancer cell cancer prevention cancer therapy cell motility college insight interdisciplinary collaboration investigator-initiated trial malignant state member mouse model neoplastic cell next generation novel novel strategies novel therapeutics patient derived xenograft model patient oriented research prognostic programs response self-renewal stem stem cells success therapy development therapy resistant translational pipeline tumor tumorigenesis

项目摘要

CELL RESPONSE AND REGULATION PROGRAM ABSTRACT The Cell Response and Regulation (CRR) Program is a basic science program at Huntsman Cancer Institute (HCI). CRR discovery science supports the Center’s mission “to understand cancer from its beginnings” by gaining new insight into basic mechanisms of cancer biology and providing a foundation for addressing critical clinical issues according to HCI’s strategic plan. CRR members use scientific ingenuity and the extensive Shared Resources provided by HCI to make new discoveries, and they collaborate with members of the Cancer Control and Population Sciences Program and the Experimental Therapeutics Program to translate these discoveries to the clinic and population in the areas of cancer prevention, target identification, biomarker development, prognostics, diagnostics, and treatment development. CRR research is centered on the following Specific Aims: 1) to elucidate mechanisms underlying cell proliferation, differentiation, and survival; 2) to uncover mechanisms and pathways mediating tumor metastasis; and 3) to understand tumor development and response to therapy. CRR is comprised of 37 members, representing 15 academic departments and four schools/colleges at the University of Utah. CRR members are well-funded, with $8.2M in peer-reviewed grant funding, of which $3.0M (33%) is from the NCI. The remainder of the peer-reviewed funding portfolio includes grants focused on cellular cancer mechanisms from the National Institutes of Health, the Department of Defense, Susan G. Komen Foundation, and the American Cancer Society. Ninety-three percent of full members have current, peer- reviewed, cancer-focused funding. In the current funding cycle, CRR members published 266 cancer-focused papers; 14% of these represent intra-programmatic collaborations, and 41% stem from inter-programmatic collaborations. The synergistic aims of the CRR Program create a highly productive, collaborative, and impactful research environment that is bolstered by the organizational capacity, infrastructure, and Shared Resources of the Cancer Center. CRR fosters excellence in basic science discovery in cancer biology; 28% of this Program’s papers were high-impact publications (journal impact factor >10). These discoveries directly led to six new investigator-initiated trials in the current funding period. Program Leaders facilitate meaningful, productive, interdisciplinary collaborations to achieve the goal of discovering and exploiting new mechanisms that underlie tumorigenesis and metastasis. Our success in collaborative intra- and inter-programmatic science is underscored by successful competition for nine new multi-principal investigator grants in the current funding period.

细胞反应和调节程序抽象的细胞响应和法规（CRR）计划是亨斯曼癌症研究所的基础科学计划（HCI）。 CRR Discovery Science支持该中心的使命“从其起源开始了解癌症” 对癌症生物学的基本机制有了新的了解，并为解决关键的基础提供了基础根据HCI的战略计划，临床问题。 CRR成员使用科学的纯质和广泛的 HCI提供的共享资源为了做出新的发现，他们与成员合作癌症控制和人口科学计划和实验治疗计划翻译这些发现在癌症预防，靶标识别，生物标志物领域的诊所和人群中发现开发，预后，诊断和治疗开发。 CRR研究集中在以下具体目的：1）阐明细胞增殖，分化和生存的机制； 2）到发现介导肿瘤转移的机制和途径； 3）了解肿瘤发育和对治疗的反应。 CRR组成了37名成员，代表15个学术部门和4所学校/学院犹他大学。 CRR会员资金充足，拥有820万美元的同行评审资金，其中300万美元（33％）来自NCI。剩余的同行评审资金组合包括专注于蜂窝的赠款国立卫生研究院，国防部Susan G. Komen的癌症机制基金会和美国癌症学会。百分之九十三的完整成员具有当前的同行审查，以癌症为中心的资金。在当前的资金周期中，CRR成员发表了266个以癌症为中心的文件;其中14％代表了截面内的合作协作。 CRR计划的协同目的创造了一项高效，协作和有影响力的研究由组织能力，基础架构和共享资源增强的环境癌症中心。 CRR促进了癌症生物学基础科学发现卓越；该计划的28％论文是高影响的出版物（期刊影响因素> 10）。这些发现直接导致了六个新的发现在当前的资助期间，研究者发动的试验。计划领导者促进有意义，富有成效，跨学科合作，以实现发现和利用基于的新机制的目标肿瘤发生和转移。我们在协作内部和程序间科学方面的成功是在当前的资金中获得了九项新的多主体调查员赠款的成功竞争的强调时期。